
-
ƯÁý : º¹Åë ( ABDOMINAL PAIN )
- ÀúÀÚ : ±è¼¼°æ ( Sei Kyung Kim )
Á¦¸ñ : ƯÁý : º¹Åë ( ABDOMINAL PAIN )
¹ßÇàÇÐȸ : ´ëÇÑÀÀ±ÞÀÇÇÐȸ
Ãâ°£³âµµ : 1991
-
10Pages l
2,500¿ø
-
- ¸®½ºÆ®Çü½Ä
-
- 10°³
-
¾à¹°À¯ÇعÝÀÀ º¸°í¿¡ ´ëÇÑ °³±¹¾à±¹ ¾à»çµéÀÇ Åµµ ¹× Áö½Ä¿¡ °üÇÑ ¿¬±¸
-
ÀúÀÚ: ±èÇö¾Æ
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 159
ÀüüÂʼö: 8
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 8pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(15) | earticle
- ű×: ¾à¹°À¯ÇعÝÀÀ, º¸°í¿¡, ´ëÇÑ, °³±¹¾à±¹, ¾à»çµéÀÇ ¹Ì¸®º¸±â
-
¸¸¼º°ñ¼ö¼º¹éÇ÷º´ ȯÀÚÀÇ È¿¿ë°¡ÁßÄ¡ ºñ±³
-
ÀúÀÚ: ÀÌÀǰæ, ÀÌÁöÇö
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 153
ÀüüÂʼö: 6
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 6pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(11) | earticle
- ű×: ¸¸¼º°ñ¼ö¼º¹éÇ÷º´, ȯÀÚÀÇ, È¿¿ë°¡ÁßÄ¡, ºñ±³ ¹Ì¸®º¸±â
-
Áö¿ª¾à±¹¿¡¼ ½ÃÇàÇÏ´Â º¹¾àÁöµµÀÇ ÁúÀû ¼öÁØ Æò°¡
-
ÀúÀÚ: ½ÅÇöÅÃ, ÀÌÁÖÇö, ¼ÕÇö¼ø
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 131
ÀüüÂʼö: 15
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 15pages | 2,500¿ø | ±¸¸Å(0) | Á¶È¸(12) | earticle
- ű×: Áö¿ª¾à±¹¿¡¼, ½ÃÇàÇÏ´Â, º¹¾àÁöµµÀÇ, ÁúÀû, ¼öÁØ ¹Ì¸®º¸±â
-
Effectiveness of Once-weekly Compared with Thrice-weekly Subcutaneous ..
-
ÀúÀÚ: ¿ÀÁ¤¹Ì, ÀÌÀ±´ö, ±è¿µÁÖ, ±è°æÀÓ, ½Å¿Ï±Õ
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 146
ÀüüÂʼö: 7
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 7pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(12) | earticle
- ű×: Effectiveness, Once-weekly, Compared, with, Thrice-weekly ¹Ì¸®º¸±â
-
Vancomycin Therapeutic Drug Monitoring ¿î¿µ ½ÇÅ Á¶»ç¿Í ¾÷¹« °³¼± ¹æ¾È
-
ÀúÀÚ: À̼÷Çâ, ±èÇØ¼÷
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 120
ÀüüÂʼö: 11
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 11pages | 2,100¿ø | ±¸¸Å(0) | Á¶È¸(17) | earticle
- ű×: Vancomycin, Therapeutic, Drug, Monitoring, ¿î¿µ ¹Ì¸®º¸±â
-
º¹¾àÁöµµ ¸¸Á·µµ°¡ º¹¾à¼øÀÀµµ¿¡ ¹ÌÄ¡´Â ¿µÇâ : ¿Ü·¡È¯ÀÚ¸¦ ´ë»óÀ¸·Î
-
ÀúÀÚ: Çã¼øÀÓ, ÇãÀçÇå, ±è¼öÁø, ±èÁÖÇõ
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 110
ÀüüÂʼö: 10
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 10pages | 2,000¿ø | ±¸¸Å(1) | Á¶È¸(14) | earticle
- ű×: º¹¾àÁöµµ, ¸¸Á·µµ°¡, º¹¾à¼øÀÀµµ¿¡, ¹ÌÄ¡´Â, ¿µÇ⠹̸®º¸±â
-
Cost-Effectiveness Analysis of Glimepiride or Pioglitazone in Combinat..
-
ÀúÀÚ: ½ÅÇöÅÃ, ÀÓ°æÈ, ¼ÕÇö¼ø, ¿ÀÁ¤¹Ì, ÀÌ¿µ¼÷
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 96
ÀüüÂʼö: 9
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 9pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(14) | earticle
- ű×: Cost-Effectiveness, Analysis, Glimepiride, Pioglitazone, Combination ¹Ì¸®º¸±â
-
ÀÔ¿øÈ¯ÀÚÀÇ °æ±¸¿ë levofloxacin ¾à¹° »ç¿ë Æò°¡
-
ÀúÀÚ: Àӱݼ÷, ³ëÀº¼÷, ¹ÚÀ±Èñ, ¹æÀº¹Ì, ±è¿ø±Ô
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 105
ÀüüÂʼö: 5
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 5pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(16) | earticle
- ű×: ÀÔ¿øÈ¯ÀÚÀÇ, °æ±¸¿ë, levofloxacin, ¾à¹°, »ç¿ë ¹Ì¸®º¸±â
-
Gemtuzumab ozogamicin°ú Ç×ü°øÇÐ
-
ÀúÀÚ: ±èÀº¿µ
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 89
ÀüüÂʼö: 7
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 7pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(13) | earticle
- ű×: Gemtuzumab, ozogamicin°ú, Ç×ü°øÇÐ ¹Ì¸®º¸±â
-
³¼ÒÁ¦°Å ÈòÁã¿¡¼ ´Ü»ï°ú ŰÅä»ê È¥ÇÕ¹°ÀÇ °ñ´Ù°øÁõ °³¼±È¿°ú
-
ÀúÀÚ: äÇÑÁ¤, ±èµµ¼º, ÇѼÛÈñ, ÀÌ¿ëö, ¹Ú¼ºÁÖ, ·ù¿ÏÈñ, ±èÇü·æ
Àú³Î¸í: Çѱ¹ÀÓ»ó¾àÇÐȸÁö
±ÇÈ£»çÇ×: Á¦19±Ç Á¦2È£
¹ßÇà±â°ü: Çѱ¹ÀÓ»ó¾àÇÐȸ
½ÃÀÛÂʼö: 75
ÀüüÂʼö: 6
- ³í¹® > ÀÇ/¾àÇÐ > ÀǾàÇмú³í¹® | µî·ÏÀÏ : 2010.08.16 | 6pages | 2,000¿ø | ±¸¸Å(0) | Á¶È¸(12) | earticle
- ű×: ³¼ÒÁ¦°Å, ÈòÁã¿¡¼, ´Ü»ï°ú, ŰÅä»ê, È¥ÇÕ¹°ÀÇ ¹Ì¸®º¸±â